PTPA and prostate cancer: To investigate the phosphorylation status of AR and MED1 as a consequence of methyl-PP2A-C loss and the resultant bias in PP2A heterotrimer formation upon LCMT1 silencing, we employed a panel of prostate cancer cell lines stably expressing shRNA to LCMT1.